- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Photodynamic therapy.
Displaying page 1 of 1.
EudraCT Number: 2018-004685-33 | Sponsor Protocol Number: NL67545 | Start Date*: 2019-05-01 |
Sponsor Name:azM | ||
Full Title: Surgical excision versus photodynamic therapy and topical 5-fluorouracil in treatment of Bowen’s disease: a multicenter randomized controlled trial | ||
Medical condition: Bowens's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003913-12 | Sponsor Protocol Number: 22/589-EC_M. | Start Date*: 2023-03-07 |
Sponsor Name:COMPLUTENSE UNIVERSITY OF MADRID | ||
Full Title: Diode laser and photodynamic therapy Versus Ciclopirox Hydroxypropyl Chitosan. Randomised controlled clinical trial. | ||
Medical condition: Onychomycosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005809-77 | Sponsor Protocol Number: NL38217 | Start Date*: 2013-01-31 |
Sponsor Name:Maastricht University Medical Centre | ||
Full Title: Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolevulinic acid 20% versus two stage topical photodynamic therapy with methylaminolevulinate | ||
Medical condition: Superficial basal cell carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003416-31 | Sponsor Protocol Number: FAEDV-2012-01 | Start Date*: 2013-02-22 |
Sponsor Name:Fundación Academia Española de Dermatología y Venereología | ||
Full Title: Multicenter, randomized, open clinical trial comparing three sessions of methyl-aminolevulinate 16% (Metvix®) photodynamic therapy versus a group without photodynamic therapy to treat onychomycosis. | ||
Medical condition: onychomycosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011897-14 | Sponsor Protocol Number: CLIN904 CCM201 | Start Date*: 2009-07-08 | |||||||||||
Sponsor Name:STEBA BIOTECH | |||||||||||||
Full Title: EVALUATION OF THE SAFETY AND EFFICACY OF WST11-MEDIATED VASCULAR TARGETED PHOTODYNAMIC THERAPY ON NON-RESECTABLE OR INOPERABLE CHOLANGIOCARCINOMA | |||||||||||||
Medical condition: Non-resectable or inoperable cholangiocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001468-34 | Sponsor Protocol Number: HLS01/2008 | Start Date*: 2008-11-20 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: Phase III clinical trial multicenter randomized for the evaluation of the safety and efficacy of the combined treatment of intravitreal triamcinolone and photodynamic therapy versus intravitreal Be... | |||||||||||||
Medical condition: Choroideal neo-vascularization type RAP. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019714-24 | Sponsor Protocol Number: 10.002 | Start Date*: 2010-09-02 | ||||||||||||||||
Sponsor Name:Research & Development Department | ||||||||||||||||||
Full Title: A phase II, open label, single site light dose escalation trial of single dose Verteporfin Photodynamic Therapy (PDT) in primary soft tissue sarcoma | ||||||||||||||||||
Medical condition: Primary soft tissue sarcoma in the upper and lower limbs of adults. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017435-18 | Sponsor Protocol Number: CLIN905 MLT202 | Start Date*: 2010-02-04 | ||||||||||||||||
Sponsor Name:Steba Biotech S.A. | ||||||||||||||||||
Full Title: A Phase IIa, Safety and Preliminary Effects Study of WST11 (Stakel®)-Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects with Choroidal Neovasularization (CNV) Associated with Age-Rel... | ||||||||||||||||||
Medical condition: Age associated Macular Degeneration | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011895-31 | Sponsor Protocol Number: CLIN903 LCM201 | Start Date*: 2009-07-08 | |||||||||||
Sponsor Name:STEBA BIOTECH | |||||||||||||
Full Title: EVALUATION OF THE SAFETY AND EFFICACY OF WST11 MEDIATED VASCULAR TARGETED PHOTODYNAMIC THERAPY ON OBSTRUCTING ENDOBRONCHIAL NON-SMALL CELL LUNG CANCER | |||||||||||||
Medical condition: Obstructive endobronchial non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003134-13 | Sponsor Protocol Number: A551109 | Start Date*: 2012-02-13 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: 5-Aminolevulinic Acid PhotoDynamic Therapy for the treatment of premalignant disorders of the vulva. | |||||||||||||
Medical condition: Premalignant vulvar disorders (usual type Vulvar Intraepithelial Neoplasia) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000110-37 | Sponsor Protocol Number: PDT-DCF-1 | Start Date*: 2013-03-18 | |||||||||||
Sponsor Name:Fundacion para la investigación biomédica del hospital Ramón y Cajal de Madrid | |||||||||||||
Full Title: Clinical effectiveness and effect on COX-2 expression of the sequential treatment of actinic keratoses (AK) with photodynamic therapy (PDT) and diclofenac 3% gel: a phase IV clinical trial. | |||||||||||||
Medical condition: Actinic keratosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004119-11 | Sponsor Protocol Number: SPECT | Start Date*: 2016-12-19 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Study on half-dose Photodynamic therapy versus Eplerenone in chronic CenTRAl serous chorioretinopathy (SPECTRA trial) | |||||||||||||
Medical condition: Chronic central serous chorioretinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018399-25 | Sponsor Protocol Number: MuSH_1.2 | Start Date*: 2011-03-17 | |||||||||||||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Zahn-,Mund-u.Kieferheilkunde,Klin.Abt.f.orale Chirurg | |||||||||||||||||||||||
Full Title: A randomized controlled trial: Photodynamic Treatment for the therapy of premalignant mucosal oral lesions. | |||||||||||||||||||||||
Medical condition: Leukoplakia and oral lichen ruber. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001781-15 | Sponsor Protocol Number: IOBA-04-2012 | Start Date*: 2012-07-31 | |||||||||||
Sponsor Name:IOBA, Universidad de Valladolid | |||||||||||||
Full Title: Initial protocol setting for the treatment of choroidal neovascularization associated to myopia magna with intravitreal bevacizumab: 3 vs 1 (BENEMCOR.es study) | |||||||||||||
Medical condition: choroidal neovascularization associated to myopia magna | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016748-38 | Sponsor Protocol Number: MAL-REG_01 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Free State of Bavaria rep. by the Univ. of Regensburg, rep. by the Regensburg Univ. Hospital | ||||||||||||||||||
Full Title: Prospective, randomized, placebo-controlled, monocentric, two-armed, observer-blinded and within-patient study for Photodynamic Therapy (PDT) with MAL in the treatment of actinic keratoses (AK) and... | ||||||||||||||||||
Medical condition: actinic keratoses and photoaged skin | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004494-41 | Sponsor Protocol Number: CLIN2001UCM301 | Start Date*: 2021-06-11 | ||||||||||||||||
Sponsor Name:Steba Biotech, S.A. | ||||||||||||||||||
Full Title: Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer | ||||||||||||||||||
Medical condition: Low Grade Upper Tract Urothelial Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012809-19 | Sponsor Protocol Number: CLIN902 PCM203 | Start Date*: 2009-07-15 | |||||||||||
Sponsor Name:STEBA BIOTECH SA | |||||||||||||
Full Title: VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCER | |||||||||||||
Medical condition: Localized prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) NL (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000944-82 | Sponsor Protocol Number: MK-3475-966 | Start Date*: 2020-03-05 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectabl... | |||||||||||||
Medical condition: Advanced and/or Unresectable Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, or Gallbladder) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004826-14 | Sponsor Protocol Number: KHB-1802 | Start Date*: 2019-01-09 | |||||||||||
Sponsor Name:Chengdu Kanghong Biotechnology Co., Ltd. | |||||||||||||
Full Title: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age related Macular Degeneration | |||||||||||||
Medical condition: Neovascular Age Related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) LV (Completed) CZ (Completed) SK (Prematurely Ended) DK (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004004-19 | Sponsor Protocol Number: QBGJ398-301 | Start Date*: 2020-02-13 | |||||||||||
Sponsor Name:QED Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGF... | |||||||||||||
Medical condition: Cholangiocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA) PT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
